
Jon Carr
36 posts



$SRRK Scholar Rock assumed with a Strong Buy at Raymond James Raymond James assumed coverage of Scholar Rock with a Strong Buy rating with a price target of $53, up from $49. Scholar Rock's apitegromab, a mAb targeting latent myostatin, is progressing towards a September 22 PDUFA date in spinal muscular atrophy, and while expectations are elevated in front of approval, apitegromab has the makings of a commercial winner, the analyst tells investors in a research note. Beyond SMA, Scholar Rock's myostatin programs have high value expansion opportunities in other neuromuscular indications, while potential outlicensing and partnerships in the obesity space can offer another source of near-term optionality, Raymond James argues!


It’s over (for now). A majority of senators caved to the fearmongering and bush league tactics of the administration and surveillance hawks in Congress, and they sold out Americans’ civil liberties. Section 702 has been reauthorized, not just without any meaningful reforms… 1/10












